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Beta-Thalassaemia-Major is a life-long genetic haemoglobin disorder requiring intensive treatment regimens, including frequent blood transfusions and daily chelation therapy. Understanding psychosocial correlates of chelation adherence is important for developing interventions to improve adherence. This study investigated within-participant correlates of oral chelation adherence on a daily (episodic) basis. Thirty seven adult participants with Beta-Thalassaemia Major were recruited from clinics at two hospitals (22 male, 9 female, mean age 34.5 years, range 19-54 years). A structured interview was used to assess behavioural and psychological situational variables related to an adherent and a non-adherent episode for each participant. Positive outcome expectancies and higher self-efficacy were both significantly associated with adherent episodes. Behavioural variables including difficulty in accessing medication, location and whether alone or with others were also associated with non-adherent episodes. Findings suggested that situational psychological factors are important for chelation adherence. Adherence interventions should consider focusing on potentially modifiable situational variables (psychological and behavioural).
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Background
Adherence to chelation therapy is vital to those living with Beta-Thalassaemia Major [1-2]. Non-adherence to the regime can have severe health consequences, including damage to vital organs and potentially death [3]. Thus gaining a detailed understanding of adherence behaviour is of the utmost importance to inform interventions to improve adherence, as well as reduce the impact of non-adherence on health and quality of life outcomes [4]. 

. 
Despite the introduction of oral chelators (e.g. Defarasirox), which are less time consuming and invasive than previous options (e.g. Deferoxamine, administered subcutaneously or intravenously) and despite the severe consequences of non-adherence, a recent study found that 10% of a sample of 245 patients reported missing 10% of their oral chelation doses or more [5]. Although this suggests higher rates of adherence than most studies of Deferoxamine adherence, where estimates have been found to range from of 59% to 98% of doses taken [6], it remains important to assess barriers to oral chelation adherence.  In particular, psychosocial barriers and facilitators are important to assess as they are potentially modifiable.
Although there have been some studies exploring the psychosocial correlates of adherence to chelation therapy in Beta-Thalassaemia Major (e.g. knowledge about treatment, psychiatric disorder, smoking, and problems preparing medication) [5, 7, 8-11], in a recent review Evangeli and colleagues found no studies that had assessed the relationship between chelation adherence and psychological variables such as self-efficacy, illness perceptions, outcome expectancies or beliefs about medication [7]. More recently, one study has identified a link between beliefs about treatment and adherence [12], indicating the relevance of psychological factors in chelation adherence.
Such factors have been identified as important in medication adherence in other conditions  [4] and are cited by theoretical models of adherence behaviour [13-17]. This suggests psychosocial factors in chelation adherence as an important area of investigation, with more potential to influence adherence interventions compared to studies investigating factors such as age or socio-economic status. 
Self-efficacy has been consistently associated with global adherence in a variety of chronic conditions [16–18]. Outcome expectations (e.g. risk cognitions) have also been frequently  associated with health behaviour (both in relation to the condition itself and the treatment) and the relationship with adherence to recommended guidelines [16-17].  Although these variables have been consistently linked to adherence behaviour in a variety of health conditions, to the authors’ knowledge, self-efficacy has not as yet been investigated in those with Beta-Thalassaemia Major taking chelation therapy, and outcome expectancies have not been examined in a within subjects design (though Trachtenberg and colleagues identified and association between treatment beliefs and chelation adherence between participants, indicating the importance of this factor [12]).
When investigating adherence patterns, differences between different groups (a ‘macro-level’) is one way of understanding the factors that predict poorer adherence (e.g. age or knowledge about treatment). Although this approach offers helpful insights, investigating adherence behaviour variations within participants (e.g. on a ‘micro-level’) has the potential to identify factors that may change for people on a daily basis, affecting their adherence. Although investigation of episodic adherence on a within participant level has been less prevalent than on a between participant level, one study has identified behavioural factors affecting episodic adherence to Anti-Retroviral Therapy in young people living with HIV using a within-participant approach [19], and daily variations in self-efficacy have been found to be associated with smoking cessation [20]. In addition, Braithwaite and colleagues found that “binge drinkers” were more likely to miss doses of medication on drinking days and post drinking days compared to non-drinking days [21]. 
In sum, there has been some focus on psychosocial correlates of global chelation adherence in Thalassaemia but (a) little examination of episodic (daily) variation using a within-patient design, and (b) limited focus on factors suggested by psychological theory. Investigating daily barriers to episodic medication adherence has the potential to provide a more detailed understanding of the situational antecedents of non-adherence, aiding the design of more adequate interventions. To address these gaps in the literature, this study focuses on situational factors in chelation adherence in Thalassaemia and, in particular, theoretically derived psychological factors drawn from socio-cognitive models of health behaviour.  Additional factors suggested from previous research, for example bodily pain, situational variables including activity and location, alcohol use, and mood, are also investigated. 
Hypothesis: 
Lower levels of self-efficacy and lower ratings of positive outcome expectances on a specific day were hypothesized to be associated with episodes (days) of non-adherence. It was also expected that additional situational variables may be associated with days of non-adherence, however as these are not theory driven variable no specific hypothesis is made.
Method
Sample and Recruitment Procedure
Participants were recruited from two London hospitals and all had a diagnosis of Beta-Thalassaemia Major, were 18 years of age or over, had been taking Deferiprone or Deferasirox for at least six months (to ensure habituation to the medication and any side effects), were able to communicate in spoken English and those included in the main analysis were able to identify at least one adherent and one non-adherent episode within the past two  months (to minimize recall bias). Deferiprone and Deferasirox have different regimen requirements (three times per day in tablet or oral solution compared to once per day in oral solution respectively). A systematic sampling strategy was employed: all those patients who met the inclusion criteria were identified by a specialist nurse using patient lists. Those who were eligible were approached initially by a nurse to facilitate introduction of the study. The first author then introduced the study details. Thirty seven out of 69 patients approached agreed to participate (a 54% recruitment rate). Thirty one (84%) could identify an episode of non-adherence in the past two months. Table 1 presents demographic information for the participant sample. 
[Insert Table 1 here]
Design
The study used a within-participant design, with each participant recalling both an adherent episode and a non-adherent episode for comparison.
Measures
Due to the novelty of conducting a within-participants design to investigate medication adherence, there were no pre-existing measures that were appropriate. Thus a structured interview was designed for the purpose of this study, similar to the design use by Hawkins and colleagues [19]. The interview was designed to include variables suggested by existing literature as well as socio-cognitive models of health behaviour. A consultation exercise with patients as well as a multi-phase piloting project was conducted to ensure participant validation of the interview. Five participants participated in the initial phase (four male participants and one female participants). They were recruited by specialist nurses at the two hospital sites. Through patient consultation and interviews the feasibility of answering questions about cognitions and feelings retrospectively was then explored. Strategies to aid memory and reduce recall bias were also explored in this phase (based on cognitive interviewing and the Day Reconstruction Method, [22]; asking questions about the day focussing on events initially and asking about psychological factors later in the interview). Following this first phase, a pilot structured interview was designed. This interview was then piloted with four participants (three male and one female participant) to explore question wording and meaning using a think-aloud technique [23], as well as exploring the ordering of questions and the length of the interview (one male participant participated in both phases of the questionnaire design).  
Behavioural variables 
Items concerning daily activities were included. A series of questions with either categorical or likert scale responses were asked about each episode. These were considered on an individual basis and covered:  Day of week, activity (same or different from usual day and if planned or unplanned), location at time of medication (at home, at work, at a friend’s / partner’s / family home, or in a public place), whether other people were present (yes/no and if so who was present), access to medication (on a five point scale: very easy to very difficult), access to items needed to take the medication (on a five point scale: very easy to very difficult) and reminder cues (person there to remind about medication or not).
Psychological variables 
Self-efficacy: The self-efficacy construct was operationalized using suggested items by Schwarzer & Renner for coping self-efficacy (confidence in one’s ability to continue a behaviour despite barriers) and a self-efficacy scale designed by Kobau and Dilorio, [15, 19]. A series of questions was asked about participants’ confidence in coping with various stages of medication use, and confidence in overcoming barriers (e.g. anticipated negative consequences) to taking the medication. For example “how confident did you feel about taking all of the medication”. The items formed a scale: response options were on a 10 point likert scale ranging from 0 (not at all confident) to 10 (very confident) and scores were combined to form a summative scale. Cronbach’s alpha for the scale (across both episodes) was 0.82 suggesting good internal reliability. Internal reliability for the adherent day alone was 0.75 and for the non-adherent day alone the alpha was 0.82, both reflecting good scale reliability.
Outcome Expectancies: A series of questions were asked about the outcome expectancies (anticipated consequences) of taking the medication at the prescribed time in the following domains: health, side effects, social (positive and negative), self: for example, feeling relieved/done right thing for self. Responses were recorded on a 5 point likert scale ranging from “not at all” to “very much so” and scores were combined to form a scale (where higher scores indicate positive outcome expectancies and lower scores indicate negative outcome expectancies). Cronbach’s alpha for the scale (across episodes) was 0.74 indicating good reliability. For the adherent day the alpha was 0 .76, and for the non-adherent day the alpha was 0.75, both indicating good scale reliability.
Mood: Positive and negative mood at the time of medication adherence/non-adherence was measured using retrospective ratings of mood on the items of the Positive and Negative Affect Scale (PANAS) (short form) [25]. The scale measures general positive and negative affect (e.g. upset / afraid / attentive / inspired) using five items that are summed for positive affect and five items summed for negative affect (each item is measured using a five point likert scale). In the present study the internal consistency of the negative mood scale on both the adherent and non-adherent day was acceptable (α=0.70 and 0.74 respectively). The internal consistency for the positive mood scale on the adherent and non-adherent day was acceptable (α=0.67 and 0.80 respectively).
Use of alcohol / drugs: A dichotomous question about whether participants had used any recreational drugs or alcohol at the time of the episode was included (e.g. yes / no), followed by amount consumed (measured on a 5 point likert scale ranging from none at all to heavy use). 
Bodily Pain: Bodily pain on the day of the episode was measured on a six point likert scale from none to very severe. 
One question was included (only for the non-adherent episode) asking participants to state to what extent they chose not to adhere (measure on a four point likert scale ranging from not at all to very much so)
An open ended question was included at the end of the interview to explore any reasons for non-adherence not included in the structured interview.
Demographic and contextual variables
Age, sex, marital status, employment, education, and living situation (alone or not alone) were assessed.
Medical variables
Serum ferritin levels were obtained from the participants’ medical records to give an indirect indication of general medication adherence [2]. 
Ethics and Procedure
The study received NHS ethical approval from an NHS Research Ethics Committee, as well as approval from a University Ethics Committee. After written consent was obtained the participants were asked to complete the initial questions on the questionnaire (demographic information and health history). Participants were asked to think back to the most recent day when they did not take their oral chelator and initially try to remember what was happening on that day, before the structured interview questions were asked. The participants were then asked to recall the last day they did adhere to their oral chelator and then completed the structured interview for the adherent day. To control for order effects the first 20 participants were asked to recall the non-adherent day first (followed by their adherent day), and the remaining participants were asked to recall their adherent day first (followed by their non-adherent day). 
Analysis
STATA (Version 10) [26] was used to analyse the data. Analyses were carried out on variables separately to investigate distributions (for continuous variables) and groupings for categorical variables. Parametric assumptions were checked for continuous variables (considering skewness and kurtosis of the distributions). For categorical variables the groupings were explored to determine if categories needed to be merged to ensure sufficient power for the analyses [26]. Initially bivariate comparisons were conducted between episodes of adherence and episodes of non-adherence. For variables conforming to parametric assumptions related sample T-tests were conducted. Where parametric assumptions were not upheld, non-parametric equivalent tests were conducted, for example Wilcoxon rank sum tests. For comparisons of categorical variables McNemar’s chi square tests were carried out. No correction of alpha level was made for self-efficacy or outcome expectancies as these were hypotheses driven. A correction was considered for the other non-hypotheses driven variables. 
Results
Table 2 presents frequencies for responses on each item of the structured interview. Responses are given for non-adherent days and adherent days for behavioural situational variables and psychological situational variables. Due to sample size and power considerations categorical variables were dichotomized: weekday was dichotomized to weekday and weekend day, location at time of medication was dichotomized to at home and not at home, and who with at time of medication was dichotomized to alone and not alone. 
[Insert Table 2 here]
Psychological Situational Variables
Paired T-tests revealed that positive outcome expectancies were significantly higher on adherent days compared to non-adherent days, (t(30)=2.46, p=0.02). Wilcoxon-signed-rank tests were carried out for self-efficacy scores (as they were negatively skewed), indicating that, in line with hypotheses, self-efficacy ratings were significantly higher on adherent days compared to non-adherent days (Z=-4.04, p<0.001). All other comparisons (the PANAS and the bodily pain rating scale) were non-significant. Further exploration of the relationship between adherent episodes, self-efficacy and outcome expectancies revealed that the relationship between outcome expectancies and adherent episodes was only significant in the cases where non-adherence was rated as intentional (t(16)=-2.16, p=0.05). When the non-adherent episode was reported as unintentional no relationship between outcome expectancies and adherent episodes was found. Self-efficacy differed significantly for both intentional non-adherent episodes and non-intentional non-adherent episodes.
Behavioural Situational Variables
There were no significant differences between the adherent day and the non-adherent day on the following variables: Someone around to remind you (χ2(1)=0.71, p>0.05), alcohol use (Z=0.86, p>0.05), or day of the week (χ2(1)=3.27, p>0.05. A Wilcoxon sign-ranks test  indicated that participants rated the difficulty of accessing medication on non-adherent days as greater than on adherent days, Z=3.139, p<0.01). McNemar Chi-Squared (exact) statistics indicated that there was a significant association between episodic adherence and location at time of medication (χ2(1)=-7.12, p<0.01): Being at home for the adherent day and not at home for the non-adherent day was more common than the other way around.  A significant association was also found between episodic adherence and activity (χ2(1)=3.60, p=0.05). Again the pattern of reporting that activity was different from usual on the non-adherent day and not different on the adherent day was more common than vice-versa.  McNemar’s Chi-Squared test indicated that there was a difference approaching significance between being alone and not being alone on adherent and non-adherent days (χ2(1)==3.60, p=0.06: It was more common to adhere on days when alone and not adhere on days when not alone than vice-versa. It should be noted that as the behavioural variables were not hypothesis driven, given the number of tests conducted, using an alpha 0.05 may lead to Type I errors due to over testing. Using a Bonferroni correction of alpha levels, a prudent alpha level would be 0.007. None of the analyses described as significant revealed alpha levels reaching this, indicating that the results should be interpreted with caution.
Discussion
This study aimed to investigate situational psychological and behavioural factors associated with episodes of adherence and non-adherence to chelation therapy in Beta Thalassaemia Major. Specifically, self-efficacy and outcome expectancies were investigated as these constructs are key constructs in many socio-cognitive models of health behaviour [13, 15, 17], have been found to be associated with adherence in other chronic conditions and have the potential to vary episodically. Additionally, behavioural situational factors (such as where people were at the time of adherence, who they were with, what they were doing and how easy it was to access medication) were also investigated, as these were suggested to be important from the literature and piloting. Additional factors were measured, including mood, physical pain and alcohol or drug use, as these had been suggested to be important in the adherence literature. 
In line with hypotheses, higher levels of situational self-efficacy were associated with episodes of adherence (in comparison to episodes of non-adherence). Self-efficacy differentiated both intentional and non-intentional non adherence. More positive outcome expectancies of taking medication were also associated with episodes of adherence, although this effect was not found when just looking at non-intentional non-adherence. Additionally, behavioural factors such as doing a different activity from usual, being away from home, not being alone, and having difficulty accessing medication were also associated with days of non-adherence. 
Self-efficacy has been consistently associated with global (between subjects) adherence in a variety of chronic conditions [19, 22, 23] and is frequently found to be strongly associated with successful performance in other domains, including educational performance, performance at work, and numerous laboratory based cognitive tasks [24–26]. Within the context of health behaviour self-efficacy has rarely been investigated as a dynamic construct, varying day-to-day within individuals, with the exception of HIV medication [10] and smoking cessation [20]. One explanation for the association between perceived self-efficacy and episodes of adherence in the present study may have been that participants’ confidence about taking their medication led to increased effort and attempts to adhere, and may have facilitated generation of strategies to overcome any barriers to adherence [32]. 
The finding that outcome expectancies only appeared to be associated with intentional non-adherence ties in with other findings from the adherence literature: For example, treatment beliefs have been shown to be associated with intentional non-adherence (choosing not to take medication), whereas they are less likely to be associated with unintentional non-adherence (e.g. forgetting) [16, 28]. 
Additional to the hypothesized relationships, a number of situational behavioural variables were also related to non-adherence in the bivariate analysis including location at time of medication (not at home compared to at home), more difficult access to medication, who with at time of medication (not alone compared to alone) and activity being different from usual. Other people being around may disrupt a usual routine or there may be social consequences to adhering to medication, for example having to disclose the condition to people who are not aware of it. People may fear stigmatising responses from others, or may not want to highlight their health condition at that particular time. If activity is different from usual they may be more likely to forget (with a lack of usual cues to memory), or they may choose not to take the medication as it may not be convenient in conjunction with the different activity. 
Understanding the situational behavioural factors may be useful from a behavioural intervention perspective as it could allow identification of new cues (in specific situations) to which the behaviour may need to be associated. For example, if an individual knows that they tend to miss their medication when they are away from home, they may need to use alternative cues or reminders specific to the alternative situation (e.g. a reminder in the car if they drive frequently). An example of a novel behavioural intervention is “electronic directly observed therapy” (involving planning and cueing, developing routines and having therapy observed (and reinforced) remotely by a health professional. There is some initial evidence that this has been helpful in improving adherence to medication in children with sickle cell disease [34]. Given the findings in the present study regarding the situational  behavioural factors associated with non-adherence, a similar approach may offer some benefit to people with Beta Thalassaemia Major managing their chelation therapy. 
Mood, physical pain and alcohol use were not found to be significantly associated with episodes of non-adherence. It is possible that episodic changes in mood may have a weaker effect than self-efficacy and outcome expectancies and would thus require a larger sample size to detect the effect. Another possibility is that an overall measure of negative mood might not capture the aspects of negative mood that might affect adherence. Some negative moods might be more likely to result in non-adherence compared to others, for example, depressed / low mood may lead to episodes of non-adherence, whereas anxiety may not have the same association. 
One of the aims of the study was to help inform interventions to improve adherence. Existing interventions have been criticized for lacking ingenuity (e.g. behavioural interventions may be generalised from other conditions and populations that may or may not present similar barriers as for people living with Beta Thalassaemia Major). It has been strongly suggested that research unpicking processes in adherence needs to be carried out to help improve interventions [35]. Of note a Cochrane review has been registered to investigate available studies of interventions to improve adherence in Thalassaemia as well as Sickle Cell Disease [36]. This review, alongside research on psychological, social and behavioural factors (such as the present study) may offer further direction and innovation in designing new interventions in the future.
Limitations
An important limitation of this study is that it relied on retrospective assessment of cognitions and emotions. When giving ratings of self-efficacy, mood and outcome expectancies, the participants already knew that they had not adhered and responses may have suffered from retrospective bias or difficulties with remembering the specific episodes. Attempts were made during the interview to separate out the conception of confidence about taking medication compared to actually taking medication. It is also noteworthy that there did not seem to be evidence of general reactivity to answering the questions on psychological situational variables: for example, there was a much larger difference between self-efficacy on adherent versus non-adherent days compared to the difference between outcome expectancies, and no difference in mood was reported. Additionally the method of Day Reconstruction Method (which guided the order of questions asked) has been used previously to reduce recall bias for retrospective accounts [22]. With regard to difficulties with memory, whilst it is hard to rule out inaccuracy of memory, a limited recall period was used (based on piloting of this aspect) and most participants described fairly recent days for their non-adherent episode (with a mean of 10 days previously), which may have limited the impact of forgetting.
Using a diary methodology would offer a different approach that would not rely as much on retrospective memory. With the use of a diary methodology the impact of mood may also be clearer, as the current study was not able to identify differences in mood between adherent and non-adherent days. It is possible that this was a type II error due to issues with recall or the measurement scale used. However, attrition can be a significant problem with diary methodology, as well as the potential for completing daily diaries to act as a prompt for medication adherence.  Future research could, however, explore the validity of using this method further by comparing prospective diary or self-report measures with retrospective accounts to explore issues with recall bias or inaccurate memory. Triangulation of methods would offer further understanding of the psychological and behavioural variables impacting adherence behaviour.
In addition, this methodology does not allow investigation of causation: whether low perceived situational self-efficacy causes non adherence. An experimental study using an intervention to improve self-efficacy would be needed to establish causation, and would be an important future direction in future research.
A further limitation of the study was the small sample size, which prevented the use of multivariate statistics (e.g. conditional logistic regression) to further explore if relationships between variables independently predicted adherent and non-adherent days. 
Participants taking either oral chelator – Deferiprone or Deferasirox – were included in the study, despite the differing regimens required. The differences in the regimen may be related to different determinants of adherence for each chelator, although there are a lack of studies comparing adherence between Deferiprone and Deferasirox. Given that the psychological factors measured in this study (self-efficacy, outcome expectancies and mood) correlate with a variety of health behaviours and adherence to medication across health conditions, there is not a strong reason to expect they would differ greatly between the regimens for the two chelators. Unfortunately the sample size was not large enough in the current study to examine correlates of adherence for each chelator separately. This is a limitation of the study and would benefit from further investigation in future research. Additionally, although serum ferritin levels were measured, given the design and sample size, it was not possible to investigate the relationship between patterns of daily adherence and clinical outcome. Further research with a larger sample size would allow comparison of patterns of episodic adherence in groups where serum ferritin was well controlled and less well controlled. Also, although information regarding participants’ pain levels was collected, it would be helpful to investigate general physical health state in relation to adherence behaviour.
One final limitation, which may affect the external validity of the findings relates to the moderate response rate. The systematic nature of the sampling, however, was a strength of the study.
Conclusion
The findings of this study suggest that psychological and behavioural situational factors are important in understanding daily variations in adherence behaviour in people living with Beta-Thalassaemia Major. Self-efficacy appeared to be particularly strongly related to episodic adherence, and moderately related to outcome expectancies. This research represents an important and novel direction in adherence research as it has demonstrated that psychological variables, such as self-efficacy and outcome expectancies, can be understood as dynamic constructs that vary within individuals, rather than as static constructs (as they are often portrayed in the adherence literature). The findings concerning the importance of certain psychological and behavioural situational variables in adherence behaviour could be used to inform interventions to improve adherence and potentially health outcomes in Beta-Thalassaemia Major.
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